$2.81
3.39% today
NYSE, Feb 05, 04:22 pm CET
ISIN
US9013841070
Symbol
TSVT
Sector
Industry

2seventy bio Stock price

$2.72
+0.08 3.03% 1M
-1.33 32.84% 6M
-0.22 7.48% YTD
-2.93 51.86% 1Y
-12.86 82.54% 3Y
-11.05 80.25% 5Y
-11.05 80.25% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.13 5.02%
ISIN
US9013841070
Symbol
TSVT
Sector
Industry

Key metrics

Market capitalization $140.32m
Enterprise Value $195.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.28
P/S ratio (TTM) P/S ratio 3.08
P/B ratio (TTM) P/B ratio 0.61
Revenue growth (TTM) Revenue growth -68.73%
Revenue (TTM) Revenue $45.62m
EBIT (operating result TTM) EBIT $-142.33m
Free Cash Flow (TTM) Free Cash Flow $-140.90m
Cash position $192.40m
EPS (TTM) EPS $-1.86
P/E forward negative
P/S forward 2.83
EV/Sales forward 3.93
Short interest 11.91%
Show more

Is 2seventy bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

2seventy bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a 2seventy bio forecast:

2x Buy
40%
2x Hold
40%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a 2seventy bio forecast:

Buy
40%
Hold
40%
Sell
20%

Financial data from 2seventy bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
46 46
69% 69%
100%
- Direct Costs 25 25
34% 34%
56%
20 20
81% 81%
44%
- Selling and Administrative Expenses 43 43
31% 31%
95%
- Research and Development Expense 111 111
49% 49%
243%
-134 -134
23% 23%
-293%
- Depreciation and Amortization 8.47 8.47
12% 12%
19%
EBIT (Operating Income) EBIT -142 -142
23% 23%
-312%
Net Profit -95 -95
49% 49%
-207%

In millions USD.

Don't miss a Thing! We will send you all news about 2seventy bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

2seventy bio Stock News

Positive
Seeking Alpha
23 days ago
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
Seeking Alpha
3 months ago
2seventy bio, Inc. (NASDAQ:TSVT ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Morgan Shields – Corporate Communications Chip Baird – Chief Executive Officer Vicki Eatwell – Chief Financial Officer Conference Call Participants Samantha Semenkow – Citi Daina Graybosch – Leerink Partners Operator Good day and thank you for standing by. Welcome to the 2seventy...
Neutral
Business Wire
3 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the third quarter ended September 30, 2024. “We are very pleased to report 42% sequential growth in quarterly Abecma sales, which was part of a continued expansion of the CAR-T class into earlier lines for multiple myeloma. When combined with the significant progress ...
More 2seventy bio News

Company Profile

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Head office United States
CEO Chip Baird
Employees 274
Founded 2021
Website www.2seventybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today